We are the only USA based cleanroom company that self-performs design, manufacture, and installation of cGMP modular cleanroom facilities. Working with AES, you can rest assured that your project is built on time and on budget, guaranteed. Our expertise in cleanroom solutions combined with our focus on your project success is second to none.
AES Clean Technology, Inc.
422 Stump Road
Montgomeryville, PA 18936
Phone: (215) 393-6810
Contact: Sales / Marketing
AES Clean Technology Manufactures Modular Cleanroom Solutions. AES utilizes modular cleanroom systems in our design-builds and modular cleanroom construction projects. The AES cleanroom wall system is made in our state of the art Suwanee, GA facility.
The Sales Manager has primary responsibility for AES business development activities within the Western Region.
If you follow these 7 steps, you will receive better responses to your cleanroom RFP and be able to identify differences and minimize risk.
Cleanroom Design, Manufacturing and Construction. AES provides complete cleanroom project delivery with guaranteed performance. Our integrated products + solutions offering provides risk mitigation with single source responsibility.
AES Clean Technology, design-builder of modular cleanroom facility solutions, announced today that Jose Jimenez has been named as its Vice President of Construction.
AES Clean Technology, a global leader in modular cleanroom manufacturing and rapid cleanroom design/build with headquarters in Montgomeryville, PA, announces the opening of a new office in Irvine, CA.
Your future cleanroom is a critical asset, it is not just another construction project. The investment you make in the cleanroom facility is significant and it should perform for years to come. Learn the relative strengths and weaknesses of various cleanroom construction methodologies that are being implemented within the marketplace.
A GMP manufacturing suite was developed from its inception by AES, which included a custom-designed and constructed Clinical Manufacturing cleanroom core for producing PENN Medicine's cell and gene therapy candidates.
It goes without saying that upgrades during a manufacturing shutdown pose less risk as there are no products being produced, but there are instances when it is critical to expand capacity or modify functionality while maintaining some processing. Following are a steps to help maintain control of production and changes—and demonstrate proof of control—while keeping the involved workers and the products safe.
In August the Novartis Institutes for Bio-Medical Research, based in Cambridge, Massachusetts, and the University of Pennsylvania’s Perelman School of Medicine (Penn Medicine) announced they had entered into an exclusive global research and licensing agreement. Under the alliance, Penn Medicine granted Novartis an exclusive worldwide license to the technologies used in an ongoing trial of patients with chronic lymphocytic leukemia (CLL) as well as future therapies based on chimeric antigen receptor (CAR) technology developed through the collaboration.